MARTIN, JOEL, H.,WANG, LI-HSIEN,STEVENS, SEAN,ALLISON, ERIN, M.
申请号:
HK10108217.8
公开号:
HK1141811B
申请日:
2010.08.30
申请国别(地区):
HK
年份:
2015
代理人:
摘要:
A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.